


Guidelines and recommendations for analyzing and interpreting GPCR second messenger data

Introduction

The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, and format) continues to generate heated debates and divergent understanding. Today, there is still a communication gap between researchers depending on their field of expertise and background, such as HTS, pharmacology, lead optimization phases, medicinal chemistry, and more.

This white paper addresses that specific topic and summarizes the results of a workshop held by Revvity with a focus group of renowned researchers in the field of GPCR biology and lead discovery (*).

Our goal was to come up with methodology recommendations on which biologists, screeners, pharmacologists, and medicinal chemists could share common understanding, and to provide guidance based on facts and results.



Focus group experts:

- Paul Groot-Kormelink & Rochdi Bouhelal (Novartis Institutes for Biomedical Research, Basel, CH),
- Olivier Corminboeuf (Idorsia Pharmaceuticals, Allschwil, CH),
- Terry Kenakin (University of North Carolina, Raleigh-Durham, USA),
- Thierry Durroux & Jean-Philippe Pin (Institut de Génomique Fonctionnelle, Montpellier, France)

Revvity contributors & experts:

- Thomas Roux, Sara Bdioui, Eric Trinquet and Pauline Scholler

I. Data analysis: what is available today?

Second messenger quantification is commonly used to monitor compound effects on G_{aq} , G_{as} and $G_{ai/o}$ coupled GPCRs. Revvity offers a wide range of kits to quantify either cyclic AMP (cAMP), the messenger related to G_{as} or $G_{ai/o}$ coupling, or inositol mono-phosphate (IP1), the messenger for G_{aq} coupling. Based on HTRF technology, Revvity kits monitor the modulation of the intracellular concentration of cAMP and IP1 through a competitive assay format using fluorescent derivatives of cAMP or IP1, detected by highly selective monoclonal antibodies (Fig. 1)

In these assays, the accumulation of the intracellular second messenger concentration induces a dose-dependent decrease of the HTRF signal. This is due to the binding modulation of the labeled antibody to the fluorescent second messenger derivatives (Fig 1a).

The kits provide IP1 or cAMP standards to build a curve enabling accurate second messenger quantification in biological samples (Fig. 1b). The dynamic range, which determines the HTRF Ratio values for which accurate quantification of second messengers is possible, is comprised between the IC_{10} and the IC_{90} values of the standard curve.

In a cell-based assay, a compound concentration-response experiment induces significant modulation of the second messenger concentration in cells, resulting in a sigmoidal curve between the HTRF signal and compound concentrations.

Using these experimental values, various methods can be applied to determine compound characteristics, such as potency (EC_{50} for agonists and IC_{50} for antagonists) and efficacy (maximal sustained response) as described Figure 2.




Figure 1: a.) HTRF second messenger assay principle (IP-One assay as an example) b.) second messenger standard curve: the IP-One assay is based on a competitive assay; the HTRF Ratio is inversely proportional to second messenger concentration. Thus, the lower the ratio, the higher the compound efficacy.




Figure 2: Second messenger compound concentration-response curve (CRC)

1. Data analysis methods

As shown in Figures 3 and 4, four methods are described to analyze the obtained experimental data. In each method, y is plotted against x , which represents the log of the stimulation compound concentration ($\log[\text{Compound}]$). In method A, the most basic of the four, the HTRF Ratio (y) is plotted against $\log[\text{Compound}]$. Using the standard curve, this data can be transformed into second messenger concentration against $\log[\text{Compound}]$, method C. When a suitable reference compound is available, both methods can be normalized to it, resulting in methods B and D respectively.

Method A: In this first analysis, HTRF Ratio curves are used to determine EC_{50} ($EC_{50} A$) and efficacy (Efficacy A) of the compound of interest (the standard curve is not used).

Method B: This analysis is based on a reference compound. In practice, the HTRF signal obtained for each concentration of compounds is normalized to that of a reference compound. Data can therefore be plotted as normalized HTRF response (%) to $\log[\text{compound}]$ from which $EC_{50} B$ and Efficacy B can be calculated.

Method C: The HTRF signal obtained with each concentration of compound is first converted into second messenger concentration by interpolating the data using the standard curve. Then, a new sigmoidal concentration-response is plotted: $[\text{second messenger}]$ to $\log[\text{compound}]$ from which $EC_{50} C$ and Efficacy C can be calculated.

Method D: This analysis requires a suitable reference compound. The first step is to convert the HTRF Ratio into $[\text{2}^{\text{nd}} \text{ messenger}]$ values. Next, $[\text{2}^{\text{nd}} \text{ messenger}]$ values are normalized to the reference cpd. Data is plotted as $[\text{second messenger}] / \text{Ref compound} (\%)$ to $\log[\text{compound}]$ from which $EC_{50} D$ and Efficacy D can be calculated.




Figure 3: Summary of four methods for data processing and analysis




Figure 4: The four methods for HTRF data analysis. Method A (no conversion of the HTRF Ratio), method B (normalized HTRF Ratio (%) with a reference compound), method C (HTRF Ratio converted in $[\text{2}^{\text{nd}} \text{ messenger}]$), and method D (normalized $[\text{2}^{\text{nd}} \text{ messenger}]$ response with a reference compound response). All sigmoidal curves are fitted using the 4PL equation: $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{-(\text{Log } IC_{50} - X) * \text{Hillslope}})$ (compound concentration-response curves as well as the standard curve).

2. Case study

The M1 receptor is known to couple preferentially to the $G_{\alpha q}$ subunit. Modulation of M1R can be monitored by detecting the IP1 second messenger using the HTRF IP-One assay. In practice, CHO cells stably expressing the muscarinic M1 receptor were treated with four well-known agonists: two full agonists, Acetylcholine (ACh) and Carbachol (CChol) displaying different potencies, and two partial agonists, TBPB and Alvimeline showing different potencies and efficacies.

In Figure 5, the agonist concentration-response curves are plotted using the four methods (A, B, C, and D) described above, using ACh as a reference compound for methods B and D. Efficacies and potencies are summarized in the table. It is clear that potencies and efficacies ranking for the various compounds is similar across the four analysis methods. However, absolute potencies and efficacies differ between HTRF Ratio (methods A and B) vs converted [2nd messenger] analysis (methods C and D). This is explained in more detail below.

	Method A		Method B		Method C		Method D	
	EC ₅₀ (nM)	Efficacy (Ratio Min)*	EC ₅₀ (nM)	Efficacy (%)	EC ₅₀ (nM)	Efficacy (nM cAMP)	EC ₅₀ (nM)	Efficacy (%)
ACH	26	3480	26	100%	84	862	84	100%
TBPB	67	4575	67	94%	249	523	250	60%
CCHOL	287	3522	289	100%	915	842	916	100%
ALVAMELINE	3038	11019	3037	58%	7954	106	7748	11%

$$EC_{50} A = EC_{50} B < EC_{50} C = EC_{50} D$$

$$\text{Efficacy A} = \text{Efficacy B} > \text{Efficacy C} = \text{Efficacy D}$$

*As the IP-One assay is based on a competitive assay, the HTRF Ratio is inversely proportional to second messenger concentration. Thus, the lower the Ratio, the higher the compound efficacy.




Figure 5: IP-One assay for M1 receptor agonist characterization using the four different analysis methods, A, B, C, and D. Efficacies and potencies for the full or partial agonists ACh, TBPB, CChol, and Alvimeline are summarized in this table using the four methods.

II. What can we learn from math and theory?

Data transformations must not skew data, either in terms of relative values and/or error. Ratio methods work well in general. However, since all assays amplify data to varying extents, absolute potency values are not useful. Only relative measures of activity compared to a standard compound can be considered useful. As such, while potency ratios can be used for full agonists, the Black Leff operational model must be used to compare full to partial agonists (Leff et al (1993 (1)); an alternative and simpler analysis utilizes Log(maximum response/EC50) (Kenakin, 2017 (2)). In that regard, the main difference between Methods A to D is system sensitivity. Thus, signal amplification from highest to lowest is: HTRF Ratio (A) = Normalized Ratio / Ref (B) > [2nd messenger] (C) = [2nd messenger] / Ref (D) (as reflected in Figure 5).

With higher amplification, full agonists appear more potent; partial agonists more efficacious (and also possibly more potent); antagonists less potent; and inverse agonist EC₅₀ less potent.

Insofar as sensitivity is an issue (such as for compound screening), methods A and B offer advantages. Otherwise, $\Delta\text{Log}(\text{max}/\text{EC}_{50})$ values for agonists do not deviate for the assay formats except for [2nd messenger] (C or D), which is slightly lower. When using the $\Delta\text{Log}(\text{max}/\text{EC}_{50})$ parameter, converting to the second messenger level is not mandatory for comparing drug activity to a standard. Nevertheless, method C and D can also provide some advantages that will be discussed section IV.

It is worth noting that, independently of the assay, the saturation of the response into the cells (biological saturation sometime referred to as “receptor reserve”, and not the saturation of the detection system itself) can also impact potency and efficacy. Indeed, saturation of the cell machinery increases the efficacy of partial agonists when compared to a full agonist, and they may even be identified as full agonists. Saturation also increases the potency (left-shifted) of the agonists.

III. What method should be chosen for compound library screening?

The main goal for compound screening is to find new chemical starting points, with accurate EC_{50} and efficacy determination being of secondary importance. To identify low potency compounds, it is therefore crucial to develop the screening assay as well as the data analysis to reflect this consideration.

In first instance, using the standard curve for reference, expression levels and cell numbers need to be adjusted to determine the ideal assay window, as described previously (3). Concerning agonists and positive allosteric modulators (PAMs), it would then be possible to increase the assay sensitivity by increasing the cell numbers slightly to make sure weak hits can be identified reliably. Conversely, to develop a suitable and sensitive screening assay in the case of antagonists, it is important to lower the cell number in order to be able to read FRET values corresponding to agonist stimulation (0% antagonism) in the dynamic range of the second messenger calibration curve. However, it is not necessary to determine the 100 % antagonism value in the highest part of the calibration curve with accuracy. On the other hand, for “MedChem” studies, it is an absolute requirement to read the full antagonism and control values within the dynamic range.

In terms of analysis methods, we recommend using either Method A or Method B (if a suitable reference compound

is available). Although EC_{50} and IC_{50} values should be very similar between both methods (Fig. 5), Method B has the advantage of fitting the concentration response curves to 100%, as well as reporting the percent of response at the maximum concentration tested, which is more intuitive than reporting the actual HTRF Ratio.

EC_{50} values determined in the screen based on Method A or B are likely to be correct with respect to the relative potency of the hits found. However, absolute potency differences between the various hits is likely to be incorrect, as they could be influenced by expression levels and cell numbers (Fig. 6). This becomes more significant once we want to further develop the hits, in which case Method A and B are not ideal. It should be emphasized that several weak hits leading to modest fluorescence increases in screening, using method A or B, do not systematically translate into hits when using method C or D (Fig. 5). As the aim of compound screening is to find as many possible chemical starting points, we recommend using Methods A or B for this phase of the drug discovery process.

IV. Recommendations for medicinal chemistry (“medchem”) and compound pharmacological characterization phases

In the context of medicinal chemistry, the main goal for compound characterization is to track relative potency changes within a certain chemical class. To achieve this, it is essential to make certain adjustments to the “MedChem” screening assay and data analysis.

In first instance, using the standard curve for reference, the expression levels and cell numbers must be adjusted to determine the ideal assay window as usual, making sure the maximum and minimum values are clearly within the dynamic range of the standard curve. If possible, frozen cells could be used, plated in the standard manner 24 hours before the experiment, to increase the robustness and consistency of receptor expression levels as well as reduce the cell culture burden. Furthermore, a standard curve should be added for each experiment, ideally on the same screening plate. For analysis in “MedChem” screening mode we recommend using either Method C or D (if a reference compound is available). Method A or B should no longer be used/reported to track relative potency.

The EC_{50} and IC_{50} values obtained with Method C or D should be very similar (Fig. 5). The advantage of using Method D is that the minimum and maximum fitting

parameters can be set to 0 and 100% (Fig. 4). Furthermore, for weak compounds where an EC_{50} and IC_{50} value cannot be determined, the percentage of activation or inhibition at the highest concentration can be given with percentage values that are interpreted easily, thereby providing potency information at the lower end of the potency range, ideal for the initial compound characterization phase.

It should be noted that with respect to agonists and PAMs, it is likely that potency will decrease when measured in the "MedChem" assay using Method C or D, as compared to the original "screening" assay (described earlier in the section "What can we learn from math and theory?"). This may be seen as a disadvantage, however, since the main goal of the compound characterization phase in the drug discovery process is to track potency improvements of individual compound classes, we recommend using only Method D (or C if no reference compound is available). Indeed, Method D (and in some cases C) display several advantages when it comes to the "MedChem" context. Firstly, it seems more accurate to report potency that is only related to a biological function and not artificially boosted due to amplification of the assay itself. Secondly, as the relative potency increase or decrease are normalized via the standard curve, they are independent on cell numbers. A further illustration on the effect of cell numbers and data obtained with the four different analysis methods is shown in Figure 6. Method A should nonetheless be used as a quality control to check whether the HTRF Ratio curve is in the dynamic range in each experiment. To avoid confusion, we recommend not reporting that aspect.

Conclusion

This article discusses the range of approaches available for processing data from immune-competitive formats, such as second messenger assays for GPCR investigation and screening. Revvity took the initiative of creating a focus group comprising several renowned experts from the industry and the academic world to address this debated question and, ultimately, to provide recommendations applicable to all researchers.

The group acknowledged that high throughput screening (HTS) and medicinal chemistry ("MedChem") are disciplines that differ in their purpose, and therefore in their data interpretation needs. While "MedChem" is concerned with revealing subtle differences in potency changes, the field of HTS puts emphasis on identifying all drug candidates. To summarize their joint conclusion:

- For HTS: Method B is the preferred analysis method. Method B consists of converting the HTRF Ratio into a percentage of a reference compound response.
- For "MedChem" and compound pharmacological characterization: Method D is the preferred analysis method. Method D is a 2-step method that consists of (1) converting the HTRF Ratio into concentrations of analyte and (2) converting the concentration of analyte into a percentage of a reference compound response.

The Revvity workshop resulted in the above consensus and, taken together, these two methods should become a reference for immune-competitive assay data interpretation throughout the drug research process, from screening to pharmacology.




Figure 6: Endogenous Beta2 Adrenergic receptor stimulation with the Isoproterenol agonist in HEK293 cells at different densities/well. The cAMP second messenger is monitored using the Gs dynamic kit. Increasing cell densities leads to a data Ratio generation outside the dynamic range of the standard curve (IC_{10} - IC_{90} , represented by dotted grey line in method A). Data is plotted using methods A, B, C, and D. The isoproterenol potency, shifted artificially, increasing the cellular density with Method A or B (EC_{50} from 6.3 to 0.6 nM), shows approximately the same potency regardless of cellular density using method C or D (EC_{50} from 13.7 to 8.9 nM). Thus, Method C and D are less sensitive to variation when data is outside the dynamic range of the standard curve.

Cells/Well	The isoproterenol agonist potency (EC50) nM			
	Method A	Method B	Method C	Method D
400	6.3	6.3	13.7	13.7
600	4.7	4.7	12.7	12.8
900	3.9	3.9	9.9	9.9
1,250	3.6	3.6	12.4	12.4
2,500	2.4	2.4	9.7	9.7
5,000	1.4	1.4	10.0	10.0
10,000	0.9	0.9	10.3	10.3
20,000	0.6	0.6	8.9	8.9

References

1. Leff, P, Dougall, I.G., Harper, D. (1993) Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting approach. *Br. J. Pharmacol.* 110: 239-244.
2. Kenakin, TP (2017), A System-Independent Scale of Agonism and Allosteric Modulation for Assessment of Selectivity, Bias, and Receptor Mutation. *Mol. Pharmacol.* 92: 1-11.
3. Refer to the second messenger user guides.

*Acknowledgements


We would like to sincerely thank all the contributors for their active participation in this workshop, including its preparation and summary:

Focus group experts:

Paul Groot-Kormelink & Rochdi Bouhelal (Novartis Institutes for Biomedical Research, Basel, CH), Olivier Corminboeuf (Idorsia Pharmaceuticals, Allschwil, CH), Terry Kenakin (University of North Carolina, Raleigh-Durham, USA), Thierry Durroux and Jean-Philippe Pin (Institut de Génomique Fonctionnelle, Montpellier, France)

Revvity contributors and experts:

Thomas Roux, Sara Bdioui, Eric Trinquet, Nicolas Pierre, Pauline Scholler, Julien Verdi, Stephanie Junique



revvity